ZURICHâ€”A drug developed by Novartis AG significantly improved the symptoms of patients with a debilitating inflammatory disease, according to data presented by the Swiss pharmaceutical giant on Saturday, setting up the prospect of another big-selling product for its portfolio.. Basel-based Novartis said AIN457, also known as secukinumab, reduced symptoms of ankylosing spondylitis in more than 60% of patients receiving the drug in two late-stage tests. By comparison, less than 29% of patients receiving a placebo showed improvements...
  